These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 15632378)

  • 61. Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?
    Pritchard KI
    Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S18. PubMed ID: 21172080
    [No Abstract]   [Full Text] [Related]  

  • 62. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
    Mbavha BT; Thelingwani RS; Chikwambi Z; Nyakabau AM; Masimirembwa C;
    Br J Clin Pharmacol; 2023 Oct; 89(10):3209-3216. PubMed ID: 37337448
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.
    Madlensky L; Natarajan L; Tchu S; Pu M; Mortimer J; Flatt SW; Nikoloff DM; Hillman G; Fontecha MR; Lawrence HJ; Parker BA; Wu AH; Pierce JP
    Clin Pharmacol Ther; 2011 May; 89(5):718-25. PubMed ID: 21430657
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
    Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
    JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer.
    Zafra-Ceres M; de Haro T; Farez-Vidal E; Blancas I; Bandres F; de Dueñas EM; Ochoa-Aranda E; Gomez-Capilla JA; Gomez-Llorente C
    Int J Med Sci; 2013; 10(7):932-7. PubMed ID: 23781139
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Antidepressants agents in breast cancer patients using tamoxifen: review of basic and clinical evidence].
    Irarrázaval O ME; Gaete G L
    Rev Med Chil; 2016 Oct; 144(10):1326-1335. PubMed ID: 28074989
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
    Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
    Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
    Higgins MJ; Rae JM; Flockhart DA; Hayes DF; Stearns V
    J Natl Compr Canc Netw; 2009 Feb; 7(2):203-13. PubMed ID: 19200418
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Individualization of tamoxifen treatment for breast carcinoma.
    Binkhorst L; van Gelder T; Mathijssen RH
    Clin Pharmacol Ther; 2012 Oct; 92(4):431-3. PubMed ID: 22910442
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
    Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
    Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
    Irvin WJ; Walko CM; Weck KE; Ibrahim JG; Chiu WK; Dees EC; Moore SG; Olajide OA; Graham ML; Canale ST; Raab RE; Corso SW; Peppercorn JM; Anderson SM; Friedman KJ; Ogburn ET; Desta Z; Flockhart DA; McLeod HL; Evans JP; Carey LA
    J Clin Oncol; 2011 Aug; 29(24):3232-9. PubMed ID: 21768473
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CYP2D6 and tamoxifen: DNA matters in breast cancer.
    Hoskins JM; Carey LA; McLeod HL
    Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.
    Thorén L; Lindh JD; Ackehed G; Kringen MK; Hall P; Bergh J; Molden E; Margolin S; Eliasson E
    Br J Clin Pharmacol; 2021 Mar; 87(3):1243-1252. PubMed ID: 32713032
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable?
    Gusella M; Pasini F; Corso B; Bertolaso L; De Rosa G; Falci C; Modena Y; Barile C; Da Corte Z D; Fraccon A; Toso S; Cretella E; Brunello A; Modonesi C; Segati R; Oliani C; Minicuci N; Padrini R;
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00646. PubMed ID: 32813313
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
    Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
    Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tamoxifen and CYP 2D6 inhibitors: caution.
    Prescrire Int; 2011; 20(118):182-4. PubMed ID: 21751753
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacogenetics of anti-estrogen treatment of breast cancer.
    Del Re M; Michelucci A; Simi P; Danesi R
    Cancer Treat Rev; 2012 Aug; 38(5):442-50. PubMed ID: 21917382
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
    Stearns V; Rae JM
    Expert Rev Mol Med; 2008 Nov; 10():e34. PubMed ID: 19019258
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
    Goetz MP; Sangkuhl K; Guchelaar HJ; Schwab M; Province M; Whirl-Carrillo M; Symmans WF; McLeod HL; Ratain MJ; Zembutsu H; Gaedigk A; van Schaik RH; Ingle JN; Caudle KE; Klein TE
    Clin Pharmacol Ther; 2018 May; 103(5):770-777. PubMed ID: 29385237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.